Back to Kentucky

SB96 • 2026

AN ACT relating to sickle cell disease.

AN ACT relating to sickle cell disease.

Passed Legislature

This bill passed both chambers and reached final enrollment, even if later executive action is not shown here.

Sponsor
G. Neal
Last action
2026-01-08
Official status
01/08/26: to Committee on Committees (S)
Effective date
Not listed

Plain English Breakdown

Using official source text because the generated explanation was unavailable or could not be confirmed against the official bill text.

AN ACT relating to sickle cell disease.

AN ACT relating to sickle cell disease.

What This Bill Does

  • AN ACT relating to sickle cell disease.

Limits and Unknowns

  • This entry is temporarily using official source text because the generated explanation could not be confirmed against the official bill text during the last sync.

Bill History

  1. 2026-01-08 Kentucky Legislative Research Commission

    introduced in Senate to Committee on Committees (S)

Official Summary Text

AN ACT relating to sickle cell disease.

Current Bill Text

Read the full stored bill text
UNOFFICIAL COPY 26 RS BR 499
Page 1 of 2
XXXX 9/3/2025 9:36 AM Jacketed
AN ACT relating to sickle cell disease. 1
Be it enacted by the General Assembly of the Commonwealth of Kentucky: 2
SECTION 1. A NEW SECTION OF KRS CHAPTER 216B IS CREATED TO 3
READ AS FOLLOWS: 4
By January 1, 2027, each hospital licensed by the Cabinet for Health and Family 5
Services shall: 6
(1) Establish policies and procedures to improve care for sickle cell disease patients 7
during hospital and emergency room visits, including: 8
(a) Expedited pain management protocols implementing standardized 9
procedures to prioritize pain relief for sickle cell disease patients within 10
thirty (30) minutes of arrival; 11
(b) Sickle cell disease medical care teams trained in sickle cell disease crisis 12
management for hospital emergency rooms; and 13
(c) Required training for all emergency room staff on sickle cell disease that 14
focuses on recognizing pain episodes, addressing care a nd treatment bias, 15
and providing culturally competent care; 16
(2) Develop programs to prevent and address addiction risks for sickle cell disease 17
patients, including: 18
(a) Alternative pain management options including nonopioid pain 19
management techniques such as cognitive behavioral therapy and 20
integrative medicine; and 21
(b) Accessible addiction treatment specifically designed for sickle cell disease 22
patients who have developed opioid dependence to ensure a holistic and 23
compassionate approach to recovery; and 24
(3) Provide patients with education and resources, including: 25
(a) Self-efficacy education on managing sickle cell disease as a chronic illness 26
and promoting independence rather than dependence on frequent hospital 27
UNOFFICIAL COPY 26 RS BR 499
Page 2 of 2
XXXX 9/3/2025 9:36 AM Jacketed
care; and 1
(b) Financial literacy workshops to help patients budget and manage finances 2
during extended hospital stays for sickle cell disease care. 3